BIIB
Biogen Inc. Common Stock
$216.78
장중 · Vol 13.2K · 52주 $133.53–$222.85 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $215.76 · Aug 31, 2026
BIIB 가격 추세
종가
$215.76
시가
$216.47
고가
$216.54
저가
$215.74
30초 브리핑
BIIB 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 93%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 13.1배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.3배
거래량은 최근 평균 범위입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
BIIB 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
225 Binney Street · Cambridge, MA, United States · 직원 7,500명
시가총액
$32.01B
Trailing P/E
38.8
최근 12개월 이익 기준
Forward P/E
13.1
이익 증가 기대 반영
EPS (TTM)
$5.64
배당 수익률
—
배당성향
0.0%
베타
0.16
시장보다 방어적
ROE
4.6%
P/B
1.70
EV/EBITDA
11.7
52주 범위
$133.53 – $222.85
현재 위치 93%
거래량
722.3K
20일 평균 569.2K · 1.3배
애널리스트 의견
매수 66%
총 35명 · 0m
DITM LEAPS Analysis
BIIB 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BIIB280121C00155000 | 1/21/28 · 1.4Y | $155.00 | $66.75 | 2.9x | 0.8904 | 7.6% | 6.74% | 32.51% | 12 | 83.37 | |
| BIIB280121C00125000 | 1/21/28 · 1.4Y | $125.00 | $106.25 | 1.8x | 0.8872 | 13.7% | 4.24% | 60.98% | 2 | 72.29 | |
| BIIB280121C00140000 | 1/21/28 · 1.4Y | $140.00 | $93.10 | 2.0x | 0.8630 | 17.7% | 4.51% | 55.04% | 30 | 71.53 | |
| BIIB280121C00150000 | 1/21/28 · 1.4Y | $150.00 | $85.75 | 2.1x | 0.8411 | 22.3% | 5.25% | 53.29% | 2,098 | 71.37 | |
| BIIB280121C00135000 | 1/21/28 · 1.4Y | $135.00 | $98.50 | 1.9x | 0.8686 | 17.1% | 4.06% | 58.70% | 3 | 69.47 | |
| BIIB280121C00165000 | 1/21/28 · 1.4Y | $165.00 | $74.75 | 2.3x | 0.8055 | 30.9% | 6.02% | 50.24% | 12 | 58.90 | |
| BIIB280121C00175000 | 1/21/28 · 1.4Y | $175.00 | $68.50 | 2.5x | 0.7757 | 39.2% | 5.84% | 51.70% | 22 | 52.31 | |
| BIIB280121C00180000 | 1/21/28 · 1.4Y | $180.00 | $65.25 | 2.5x | 0.7619 | 43.8% | 6.90% | 51.16% | 14 | 48.16 |
재무제표
BIIB 연간 손익·현금흐름·재무상태
매출 성장률
+2.2%
최근 연간 YoY
EPS 성장률
-21.4%
최근 연간 YoY
영업이익률
25.0%
최근 연간
FCF 마진
19.9%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $9.89B+2.2% | $9.68B-1.6% | $9.84B-3.3% | $10.17B |
| 매출총이익 | $7.49B+1.6% | $7.37B+0.9% | $7.30B-7.5% | $7.90B |
| 영업이익 | $2.47B+8.3% | $2.28B+23.4% | $1.85B-36.3% | $2.90B |
| 순이익 | $1.29B-20.8% | $1.63B+40.6% | $1.16B-61.9% | $3.05B |
| 희석 EPS | $8.79-21.4% | $11.18+40.3% | $7.97-61.8% | $20.87 |
| EBITDA | $2.60B-8.0% | $2.83B+38.8% | $2.04B-53.2% | $4.36B |
| 영업현금흐름 | $2.20B-23.3% | $2.88B+85.9% | $1.55B+11.8% | $1.38B |
| 잉여현금흐름 | $1.97B-21.7% | $2.52B+103.6% | $1.24B+8.3% | $1.14B |
| 총자산 | $29.44B+5.0% | $28.05B+4.5% | $26.84B+9.3% | $24.55B |
| 총부채 | $6.58B-0.8% | $6.63B-9.6% | $7.34B+10.9% | $6.61B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
BIIB 실적·배당 일정
매출 하단
$2.50B
EPS 하단
$1.44
매출 상단
$2.73B
실적 발표일
2026-10-29
D-58
EPS 상단
$2.67
매출 컨센서스
$2.64B
EPS 컨센서스
$2.04
뉴스
BIIB 관련 최신 기사
제품·기술Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]
Insider Monkey · Aug 30, 2026
실적Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · Aug 28, 2026
- 실적
Veeva Systems Inc (VEEV) (Q2 2027) Earnings Call Highlights: Record CRM Quarter and AI Momentum ...
Veeva Systems Inc (VEEV) reports $928 million in revenue and best-ever CRM performance, with Veeva Falcon AI gaining traction.
GuruFocus.com · Aug 27, 2026
실적Veeva Systems Q2 Earnings Call Highlights
Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment
MarketBeat · Aug 26, 2026
- 실적
Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says
Veeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science
MT Newswires · Aug 25, 2026
제품·기술3 Reasons to Sell BIIB and 1 Stock to Buy Instead
Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.4% to $218.22 per share while the index has gained 10.5%.
StockStory · Aug 25, 2026
실적Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?
Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 year total shareholder returns. This...
Simply Wall St. · Aug 21, 2026
- 실적
What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders
In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined with investor attention on five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs, has become a central focus in reassessing the company’s long-term profile. Next, we’ll examine how Biogen’s higher earnings guidance and advancing...
Simply Wall St. · Aug 21, 2026
M&AShould You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
Zacks · Aug 20, 2026
일반Is Wall Street Bullish or Bearish on Biogen Stock?
Biogen has notably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
Barchart · Aug 20, 2026
홀더
BIIB 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
99.5%
기관 보유 (유동주식)
99.7%
내부자 보유
0.2%
기관 수
1,489
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| FMR, LLC | 18.22M | $3.95B | 12.3% | 42.2% | Jun 30, 2026 |
| Blackrock Inc. | 15.99M | $3.46B | 10.8% | 0.1% | Jun 30, 2026 |
| Primecap Management Company | 15.15M | $3.28B | 10.3% | 2.7% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 9.65M | $2.09B | 6.5% | 1.2% | Jun 30, 2026 |
| State Street Corporation | 7.34M | $1.59B | 5.0% | 2.5% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 6.60M | $1.43B | 4.5% | 1.1% | Jun 30, 2026 |
| Geode Capital Management, LLC | 4.45M | $963.94M | 3.0% | 2.5% | Jun 30, 2026 |
| Wellington Management Group, LLP | 3.12M | $675.40M | 2.1% | 5.3% | Jun 30, 2026 |
| NORGES BANK | 2.58M | $558.96M | 1.8% | -2.2% | Jun 30, 2026 |
| Morgan Stanley | 2.41M | $522.40M | 1.6% | 11.1% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.